chemieunternehmen.com

Evotec AG today announced that it has been awarded a research grant from The Michael J. Fox Foundation („MJFF“) to further develop Evotec’s TargetaSN (Targetalpha-synuclein) programme for the treatment of Parkinson’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-awarded-grant-from-the-michael-j-fox-foundation-for-parkinsons-research-5339

Evotec AG today announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. („Janssen“) for the transition of a project into further drug discovery process. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-important-milestone-in-targetad-collaboration-with-janssen-in-alzheimers-disease-5335

Evotec AG today announced an EVT Execute collaboration aimed at providing a complete solution to UCB’s global sample management requirements. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ucb-sign-multi-year-sample-management-agreement-5333

Evotec AG today announced an extension of an existing collaboration with Spero Therapeutics, based in Cambridge, Massachusetts, aimed at discovering and developing new and ground-breaking therapeutics for Gram-negative bacteria to treat serious infections and address the growing threat to global public health resulting from antibiotic resistance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-spero-therapeutics-extend-collaboration-to-develop-novel-antibacterials-10

Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached two important pre-clinical milestones for the transition of two projects from the alliance portfolio into late-stage discovery and pre-clinical development for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-important-pre-clinical-milestones-as-part-of-its-multi-target-alliance-with-bayer-healthcare-11

Hamburg, Germany – 20 November 2015: Evotec announced that Charles Sabine, former Emmy-awarded NBC News journalist and a high-profile spokesman for the global Huntington’s disease community, gave a lecture on “Why … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/huntingtons-disease-and-the-hope-for-a-treatment-5324

– STRONG GROWTH IN REVENUES AND PROFITS – THREE MAJOR EVT INNOVATE DEALS CONCLUDED – REVENUE GUIDANCE RAISED ON 15 SEPTEMBER 2015 Hamburg, Germany – 10 November 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-the-first-nine-months-of-2015-5321

Evotec AG today announced an EVT Execute collaboration with Beyond Batten Disease Foundation aimed at discovering and developing new treatments for juvenile Batten disease, a rare, fatal autosomal recessive neurodegenerative disorder.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-beyond-batten-disease-foundation-collaborate-to-advance-emerging-therapies-to-fight-juvenile-batten-disease-5317

Evotec AG today announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute, Department of Health and Human Services.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-awarded-multi-year-contract-to-manage-national-cancer-institute-chemical-biology-consortium-screening-libraries-center-5315